Skip to main content Skip to navigation

Apply for funding

Round 1 is now closed, please see Round 2 for information

Warwick has been awarded £600,000 from the Wellcome Trust for a Warwick-Wellcome Trust Translational Partnership award. Warwick is supporting the Translational Partnership with £180,000 from HEIF. The Warwick-Wellcome Trust Translational Partnership will focus on investing in fellowships and projects aimed at exploiting emerging impact in the science of early life, tissue models of human disease and disease control and prevention. The Warwick-Wellcome Trust Translational Partnership will provide supporting expertise in impact delivery and will strengthen links to partner institutions in industry and the local hospital network.


Funding Programmes

Three funding programmes are available to support people, translational funding and embedding of a biomedical translational research culture:

  • Translation Fellowships to provide the opportunity for researchers to engage with translational research activities and take forward opportunities. Longer term funding (1-2 years) is available for a dedicated researcher to drive forward translational research arising from their own research or that of the research group. It is anticipated that around three awards will be made.
  • Translation and Innovation Grants to provide project-focussed pump priming awards to overcome specific barriers and/or directed towards later stage projects that need support to move to the next technology readiness level. Applications to buy out UHCW clinician’s time for a translational project would also be welcome. It is anticipated that around 8 awards will be made.
  • Breaking Translational Barriers Awards to provide smaller awards of up to £10,000 to access bespoke external expertise and advice on the potential of the idea or technology and overcome well-defined barriers, for example engaging end users and networks, commissioning market research analyses and exploring routes to market to progress their research along the translational pipeline. The Breaking translational barriers awards will not fund Warwick staff time. Contact to find out more.

The partnership welcomes applications from applicants who have not been previously involved in translation.


Applicants should normally be a University academic employee, or be the holder of a personal research fellowship awarded competitively, with a contract lasting the duration of the project. UHCW-employed clinicians are also eligible and applications must provide an accompanying letter from the Clinical Director confirming support for the project. If funding is requested for buy-out time for clinicians a signed letter of support and commitment to the dedicated research time from the Clinical Director is required.

How to Apply

Translational Fellowship and Translation and Innovation Grant applications must be submitted on the Warwick-Wellcome Trust Translational Partnership Application Form to by 1st February 2020. Please refer to the documents below for full guidance, a copy of the application form and the terms and conditions of the awards.

Documents for application

Please contact to discuss the Breaking translational barriers awards to access bespoke external expertise and advice.

Top tips for success

Successful proposals:

  • Explained the context for the proposed work and how it would address a societal, clinical and patient need
  • Described the current position on the translational development pathway and anticipated progress
  • Provided clear plans for future translational and impact activities and funding strategies, and how the proposed work would support these
  • Included sufficient preliminary data and detail, particularly if the proposed activity was reliant on specific technologies or transferable to other drugs or challenges
  • Provided clear and feasible milestones, and deliverables
  • Assembled a strong team comprising the relevant expertise, including relevant external stakeholders
  • Offered value for money

Unsuccessful proposals:

  • Were not translational research and more suited to external responsive mode funding schemes
  • Were too early on the translational development pathway to be eligible for the Translation-al Partnership
  • Were not innovative or other translational and funding routes were more appropriate
  • Did not provide sufficient information on relevant context, e.g. relevant regulation considerations
  • Did not provide sufficient information on the proposed methodologies and evidence of prior success